XRTX
Income statement / Annual
Last year (2023), XORTX Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, XORTX Therapeutics Inc.'s net income was -$2.15 M.
See XORTX Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
02/28/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$141.96 K
|
$75.27 K
|
$17.88 K
|
$20.44 K
|
$19.90 K
|
$19.32 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$141.96 K
|
-$75.27 K
|
-$17.88 K
|
-$20.44 K
|
-$19.90 K
|
-$19.32 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$2.41 M
|
$6.49 M
|
$669.11 K
|
$277.46 K
|
$39.90 K
|
$342.25 K
|
$66.37 K
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$1.07 M
|
$2.29 M
|
$1.58 M
|
$1.10 M
|
$506.17 K
|
$795.65 K
|
$380.92 K
|
$389.32 K
|
$36.92 K
|
| Selling & Marketing Expenses |
$1.33 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$2.39 M
|
$2.29 M
|
$1.58 M
|
$1.10 M
|
$506.17 K
|
$795.65 K
|
$380.92 K
|
$389.32 K
|
$36.92 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$2.64 M
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$4.81 M
|
$9.86 M
|
$2.86 M
|
$1.30 M
|
$565.97 K
|
$1.16 M
|
$464.07 K
|
$405.34 K
|
$36.92 K
|
| Cost And Expenses |
$4.81 M
|
$9.86 M
|
$2.86 M
|
$1.30 M
|
$565.97 K
|
$1.16 M
|
$464.07 K
|
$405.34 K
|
$36.92 K
|
| Interest Income |
$257.65 K
|
$101.37 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$4.39 K
|
$13.51 K
|
$37.21 K
|
$22.30 K
|
$15.46 K
|
$8.63 K
|
$0.00
|
| Depreciation & Amortization |
$141.96 K
|
$75.27 K
|
$17.88 K
|
$20.44 K
|
$19.90 K
|
$19.32 K
|
$16.78 K
|
$16.02 K
|
$0.00
|
| EBITDA |
-$4.87 M |
-$9.41 M |
-$1.63 M |
-$1.25 M |
-$572.47 K |
-$1.07 M |
-$427.11 K |
-$389.32 K |
-$36.92 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.65 M
|
$2.95 M
|
$1.25 M
|
-$202.36 K
|
-$63.61 K
|
-$2.71 M
|
-$47.09 K
|
-$25.52 K
|
$0.00
|
| Income Before Tax |
-$2.15 M
|
-$6.99 M
|
-$1.30 M
|
-$1.28 M
|
-$629.58 K
|
-$3.78 M
|
-$474.20 K
|
-$414.83 K
|
-$36.92 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$4.39 K
|
$13.51 K
|
$37.21 K
|
$22.30 K
|
$10.09 K
|
$8.63 K
|
$0.00
|
| Net Income |
-$2.15 M
|
-$6.99 M
|
-$1.30 M
|
-$1.28 M
|
-$629.58 K
|
-$3.78 M
|
-$474.20 K
|
-$414.83 K
|
-$36.92 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.08 |
-4.72 |
-1.19 |
-1.73 |
-1.06 |
-6.45 |
-2.24 |
-2.05 |
-0.49 |
| EPS Diluted |
-1.08 |
-4.72 |
-1.19 |
-1.73 |
-1.06 |
-6.45 |
-2.24 |
-2.05 |
-0.49 |
| Weighted Average Shares Out |
$1.98 M
|
$1.48 M
|
$1.09 M
|
$740.45 K
|
$595.49 K
|
$584.99 K
|
$211.45 K
|
$202.74 K
|
$75.57 K
|
| Weighted Average Shares Out Diluted |
$1.98 M
|
$1.48 M
|
$1.09 M
|
$740.45 K
|
$595.49 K
|
$584.99 K
|
$211.45 K
|
$202.74 K
|
$75.57 K
|
| Link |
|
|
|
|
|
|
|
|
|
